TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin Monotherapy in Treatment-Refractory Germ Cell Tumors at the ESMO Congress 2026
Objective response rate of 45.5% and disease control rate of 72.7% observed in 11 heavily pretreated patients with recurrent germ cell tumors Responses observed in three of six patients with disease progression after high-dose chemotherapy and autologous stem cell transplantation, a...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


